Shares of Axsome Therapeutics Inc. (AXSM) tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd. (TEVA.TV) is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome's depression treatment. Axsome's stock has gained 95.8% over the past year, while the S&P 500 declined 7.6%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.